# EDGAR Filing Document

**Accession Number:** 0001411690
**File Stem:** 0001411690-25-000082
**Filing Date:** 2025-8
**Character Count:** 36091
**Document Hash:** 659a60d93695aced2a048c74d7fc0a2e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001411690-25-000082.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001411690-25-000082

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250814

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bionano Genomics, Inc.
- **CENTRAL INDEX KEY:** 0001411690
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 261756290
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38613
- **FILM NUMBER:** 251218642

**BUSINESS ADDRESS:**
- **STREET 1:** 9540 TOWNE CENTRE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 888-7600

**MAIL ADDRESS:**
- **STREET 1:** 9540 TOWNE CENTRE DRIVE
- **STREET 2:** SUITE 100
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Bionano Genomics, Inc
- **DATE OF NAME CHANGE:** 20190308

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioNano Genomics, Inc
- **DATE OF NAME CHANGE:** 20120703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BioNanomatrix Inc
- **DATE OF NAME CHANGE:** 20070906

?xml version='1.0' encoding='ASCII'? bngo-20250814

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** August 14, 2025

**Bionano Genomics, Inc.**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38613** | **26-1756290** |
| (State or Other Jurisdiction<br>of Incorporation) | (Commission<br>File Number) | (IRS Employer<br>Identification No.) |
| **9540 Towne Centre Drive, Suite 100**<br>**San Diego, California** | **9540 Towne Centre Drive, Suite 100**<br>**San Diego, California** | **92121** |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(858) 888-7600**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ &nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ &nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | BNGO | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition.**

On August 14, 2025, Bionano Genomics, Inc. (the "Company") issued a press release reporting its financial results for the second quarter ended June 30, 2025. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information contained or incorporated into this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

**Forward-Looking Statements**

This Current Report on Form 8-K contains "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding product uptake, revenue, flowcell usage by customers we consider to be routine users of OGM, market development and OGM adoption, including as evidenced through publications highlighting the utility and applications of OGM, our commercial prospects and future financial and operating results, including our full year 2025 and Q3 2025 revenue guidance, cash runway, expected impact from our cost savings initiatives and additional plans to reduce our annualized cost structure and the timing for such savings; the growth of our installed base of OGM systems; our expectation that our products and innovations will be drivers of future growth; the sales of our flowcell consumables and the other expectations related thereto; our ability to meet our stated goals, including to drive value and penetrate into our target markets; our commercial expectations, including the potential market opportunity for structural variation analysis and OGM; our commercial opportunities related to our OGM systems and our analysis software; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; and our ability to drive adoption of OGM and our technology solutions. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the timing and amount of revenue we are able to recognize in a given fiscal period; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a "going concern," which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; the risk that we are not able to complete a strategic transaction that would increase stakeholder value; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

------

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | <u>[Press release issued August 14, 2025, reporting financial results for the second quarter ended June 30, 2025](a2025-06x30bngox2qearnings.htm)</u> |
| 104 | Inline XBRL for the cover page of this Current Report on Form 8-K |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** |
| Date: August 14, 2025 | By: | /s/ R. Erik Holmlin, Ph.D. |
|  |  | R. Erik Holmlin, Ph.D. |
|  |  | President and Chief Executive Officer<br>(Principal Executive and Financial Officer) |

---

## Exhibit 99.1

---

| | |
|:---|:---|
| ![picture3.jpg](picture3.jpg) | ![picture4.jpg](picture4.jpg) |

---

**Bionano Reports Second Quarter 2025 Results and Highlights Recent Business Progress** 

Conference call today, August 14, 2025, at 4:30 PM ET

SAN DIEGO, August 14, 2025 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2025.

"We continued to execute on our new strategy of focusing on our base of routine users of optical genome mapping (OGM) and VIA™ software as the primary drivers of our revenue and gross profit in the second quarter. These routine users are increasingly leveraging our OGM systems and software and we believe the recent upgrades to our software and compute platforms will drive further utilization. I'm very proud of our team for driving gross margin above 50% this quarter, which combined with our continued efforts to reduce costs, gives us confidence that our strategy shift is working," commented Erik Holmlin, PhD, president and CEO of Bionano.

**Q2 2025 Financial Results**

For the three-month period ended June 30, 2025, as compared to the same period of 2024:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reported total revenue of $6.7 million, representing a decrease of 13% from $7.8 million in Q2 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ The prior year period included $0.7 million in revenue from clinical services, which were discontinued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Consumables and software revenues increased 16%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ The prior year period also included $2.3 million in instrument revenue, compared to $1.4 million in the second quarter of 2025, driven by the Company's new strategy focusing on routine users rather than new instrument placements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ When adjusting for instrument sales and discontinued clinical services, combined revenue for consumables, software and remaining services and other sources increased 11%.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Sold 7,233 nanochannel array flowcells in the second quarter, which was an increase of 17% over the 6,165 flowcells sold in the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Installed 7 new OGM systems and brought 8 back to reach an installed base of 378 at quarter-end, representing a 4% increase over the 363 installed systems reported at the end of the second quarter of 2024

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Generated gross margin of 52%, compared to 33% for the second quarter of 2024, and non-GAAP gross margin<sup>1</sup> of 52%, compared to 35% for the second quarter of 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reduced operating expenses by 42% to $11.3 million and non-GAAP operating expense<sup>1</sup> by 53% to $8.8 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Ended the second quarter with cash, cash equivalents, available-for-sale securities, and restricted short-term investments of $27.4 million.

**Recent Business Highlights:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced upgrades to VIA and Solve™ software for genomic data analysis and Stratys™ Compute server to make analysis of OGM, microarray, and NGS data easier, faster, and more accurate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Achieved a new quarterly record with 119 peer-reviewed publications, highlighting the growing utilization of OGM.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Demonstrated utility of OGM through 16 studies, including oral presentations and posters, at the biennial meeting of the European Cytogenomics Conference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Highlighted the differentiated utility of OGM in detecting structural variants associated with genetic diseases, including constitutional disorders, hematological malignancies and solid tumors through 21 oral presentations and posters at the European Society of Human Genetics (ESGH) conference.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced the editorial panel of the American Medical Association (AMA) established a second Category I Current Procedural Terminology (CPT) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations relative to constitutional genetic disorders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Announced a new publication in HemaSphere demonstrating the utility of OGM for analysis of infant and toddler T-cell acute lymphoblastic leukemia (T-ALL).

------

**2025 Outlook**

We anticipate the following results for Q3 2025 and the full year:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reiterating full year 2025 revenue in the range of $26.0 to $30.0 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Initiating Q3 2025 revenue in the range of $6.7 to $7.2 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Increasing new OGM installation expectations to 20 to 25 in full year 2025, compared to prior expectations of 15 to 20.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash runway into the first quarter of 2026 enabled by cost savings and capital efficiency together with debt restructuring and equity capital raised at year-end and early January.

**Webcast Details** 

---

| | |
|:---|:---|
| *<u>Webcast Details</u>* |  |
| Date: | Thursday, August 14, 2025 |
| Time: | 4:30 p.m. Eastern Time |
| Participant Registration: | https://edge.media-server.com/mmc/p/tnombut6/ |
| Webcast: | https://register-conf.media-server.com/register/BI297e698f44e44875bbaabfd86711a04a |

---

Participants should register at the link above in advance of the call, and then click the webcast link before the call begins. An archived version of the webcast will be available for replay in the Investors section of the Bionano website.

<sup>1"</sup>Non-GAAP gross margin" and "non-GAAP operating expense" are non-GAAP financial measures. Please refer to the section titled "Non-GAAP Financial Measures" below for a description of the non-GAAP financial measures used herein. Reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this release.

------

**About Bionano** 

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company's mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.

Bionano's products are for research use only and not for use in diagnostic procedures.

**Non-GAAP Financial Measures**

To supplement Bionano's financial results reported in accordance with U.S. generally accepted accounting principles (GAAP), the Company has provided non-GAAP gross margin and non-GAAP operating expense in this press release and the accompanying conference call, each of which is a non-GAAP financial measure. Non-GAAP gross margin excludes from gross margin reported in accordance with GAAP: stock-based compensation and restructuring expenses. Non-GAAP operating expense excludes from operating expense reported in accordance with GAAP: stock-based compensation, amortization of intangibles, changes in fair value of contingent consideration, transaction-related expenses, and loss on disposals. In addition, our reconciliation table provided at the end of this release contains certain additional non-GAAP metrics, including non-GAAP cost of revenue, non-GAAP selling, general and administrative expense, non-GAAP research and development expense, non-GAAP intangible assets and other long-lived assets impairment and non-GAAP restructuring costs, each with adjustments as presented in the table.

Bionano believes that each of these non-GAAP metrics is useful to investors and analysts as a supplement to its financial information prepared in accordance with GAAP for analyzing the Company's performance and identifying trends in its business. Bionano uses these non-GAAP metrics internally to facilitate period-to-period comparisons and analysis of its performance in order to understand, manage and evaluate its business, to make operating decisions, and for forecasting and budgeting. Accordingly, Bionano believes presentation of these non-GAAP measure allows for greater transparency with respect to key financial metrics it uses in assessing its own operating performance and making operating decisions.

These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, each non-GAAP financial measure as used by Bionano in this press release and the accompanying reconciliation table has limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

For a reconciliation of non-GAAP gross margin to gross margin reported in accordance with GAAP and non-GAAP operating expense to operating expense reported in accordance with GAAP, please refer to the financial tables accompanying this press release.

------

**Forward-Looking Statements of Bionano Genomics**

This press release and the accompanying conference call contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy and plans, and objectives of management for future operations, are forward-looking statements. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding product uptake, revenue, flowcell usage by customers we consider to be routine users of OGM, market development and OGM adoption, including as evidenced through publications highlighting the utility and applications of OGM, our commercial prospects and future financial and operating results, including our full year 2025 and Q3 2025 revenue guidance, cash runway, expected impact from our cost savings initiatives and additional plans to reduce our annualized cost structure and the timing for such savings; the growth of our installed base of OGM systems; our expectation that our products and innovations will be drivers of future growth; the sales of our flowcell consumables and the other expectations related thereto; our ability to meet our stated goals, including to drive value and penetrate into our target markets; our commercial expectations, including the potential market opportunity for structural variation analysis and OGM; our commercial opportunities related to our OGM systems and our analysis software; continued research, presentations and publications involving OGM, its utility compared to traditional cytogenetics and our technologies; and our ability to drive adoption of OGM and our technology solutions. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the timing and amount of revenue we are able to recognize in a given fiscal period; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts and our ability to continue as a "going concern," which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the impact of adverse geopolitical and macroeconomic events, such as the ongoing conflicts between Ukraine and Russia and Israel and Gaza and uncertain market conditions, including inflation, tariffs, and supply chain disruptions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; changes in our strategic and commercial plans; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; study results that differ or contradict the results mentioned in this press release; the risk that we are not able to complete a strategic transaction that would increase stakeholder value; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

------

**CONTACTS**

**Company Contact:**

Erik Holmlin, CEO

Bionano Genomics, Inc.

+1 (858) 888-7610

eholmlin@bionano.com

**Investor Relations:**

Kelly Gura

Gilmartin Group

+1 (212) 229-6163

IR@bionano.com

------

---

| | | |
|:---|:---|:---|
| **BIONANO GENOMICS, INC** | **BIONANO GENOMICS, INC** | **BIONANO GENOMICS, INC** |
| **Condensed Consolidated Balance Sheet (Unaudited)** | **Condensed Consolidated Balance Sheet (Unaudited)** | **Condensed Consolidated Balance Sheet (Unaudited)** |
| | **(Unaudited)** | |
| | **June 30, 2025** | **December 31, 2024** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $3562000 | $9173000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments | 12876000 | 302000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 3493000 | 4752000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | 8633000 | 11121000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 3098000 | 3141000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted investments | 11000000 | 11000000 |
| Total current assets | 42662000 | 39489000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restricted cash |  | 400000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment, net | 17264000 | 19219000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use asset | 3772000 | 1804000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Financing lease right-of-use asset | 3198000 | 3299000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets, net | 7025000 | 9705000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term assets | 2089000 | 2754000 |
| Total assets | $76010000 | $76670000 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $6244000 | $6962000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses | 3405000 | 5641000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract liabilities | 1165000 | 1128000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability | 1348000 | 2991000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease liability | 254000 | 260000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Convertible debentures payable (at fair value) | 11762000 | 20362000 |
| Total current liabilities | 24178000 | 37344000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liability, net of current portion | 2704000 | 145000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance lease liability, net of current portion | 3511000 | 3539000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Long-term contract liabilities | 243000 | 267000 |
| Total liabilities | 30636000 | 41295000 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred Stock |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 748568000 | 728573000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (703184000) | (693225000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive income (loss) | (10000) | 27000 |
| Total stockholders' equity | 45374000 | 35375000 |
| Total liabilities and stockholders' equity | $76010000 | $76670000 |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** |
| **Condensed Consolidated Statement of Operations (Unaudited)** | **Condensed Consolidated Statement of Operations (Unaudited)** | **Condensed Consolidated Statement of Operations (Unaudited)** | **Condensed Consolidated Statement of Operations (Unaudited)** | **Condensed Consolidated Statement of Operations (Unaudited)** |
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Product revenue | $6310000 | $6510000 | $12314000 | $13338000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Service and other revenue | 423000 | 1261000 | 876000 | 3202000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenue | 6733000 | 7771000 | 13190000 | 16540000 |
| Cost of revenue: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of product revenue | 3150000 | 4703000 | 6202000 | 9607000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of service and other revenue | 106000 | 483000 | 572000 | 1525000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cost of revenue | 3256000 | 5186000 | 6774000 | 11132000 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 2931000 | 6831000 | 5299000 | 16608000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling, general and administrative | 8346000 | 11557000 | 17379000 | 30644000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets and other long-lived assets impairment |  |  |  | 448000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs |  | 1215000 |  | 5847000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 11277000 | 19603000 | 22678000 | 53547000 |
| Loss from operations | (7800000) | (17018000) | (16262000) | (48139000) |
| Other income (expenses): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 277000 | 457000 | 566000 | 1500000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income (expense) | 676000 | 363000 | 5756000 | (998000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income (expense) | 953000 | 820000 | 6322000 | 502000 |
| Loss before income taxes | (6847000) | (16198000) | (9940000) | (47637000) |
| Provision for income taxes | (10000) | (26000) | (18000) | (9000) |
| Net loss | $(6857000) | $(16224000) | $(9958000) | $(47646000) |

---

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** | **Bionano Genomics, Inc.** |
| **Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)** | **Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)** | **Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)** | **Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)** | **Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)** |
| | **Three Months Ended June 30,** | **Three Months Ended June 30,** | **Six Months Ended June 30,** | **Six Months Ended June 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| GAAP gross margin: |  |  |  |  |
| GAAP revenue | $6733000 | $7771000 | $13190000 | $16540000 |
| GAAP cost of revenue | 3256000 | 5186000 | 6774000 | 11132000 |
| &nbsp;&nbsp;&nbsp;&nbsp;GAAP gross profit | 3477000 | 2585000 | 6416000 | 5408000 |
| &nbsp;&nbsp;&nbsp;&nbsp;GAAP gross margin % | 52% | 33% | 49% | 33% |
| Non-GAAP gross margin: |  |  |  |  |
| GAAP revenue | $6733000 | $7771000 | $13190000 | $16540000 |
| GAAP cost of revenue | 3256000 | 5186000 | 6774000 | 11132000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | (40000) | (128000) | (77000) | (256000) |
| &nbsp;&nbsp;&nbsp;&nbsp;COGS restructuring |  | (7000) |  | (18000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP cost of revenue | 3216000 | 5051000 | 6697000 | 10858000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP gross profit | 3517000 | 2720000 | 6493000 | 5682000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP gross margin % | 52% | 35% | 49% | 34% |
| GAAP operating expense |  |  |  |  |
| &nbsp;&nbsp;&nbsp;GAAP selling, general and administrative expense | $8346000 | $11557000 | $17379000 | $30644000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | (880000) | (2341000) | (2180000) | (4057000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Intangible asset amortization | (1340000) | (1714000) | (2680000) | (3506000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in fair value of contingent consideration |  | 4476000 |  | 5116000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Transaction related expenses | (63000) | 91000 | (126000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Loss on disposals |  |  |  | (374000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP selling, general and administrative expense | 6063000 | 12069000 | 12393000 | 27823000 |
| &nbsp;&nbsp;&nbsp;GAAP research and development expense | $2931000 | $6831000 | $5299000 | $16608000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock-based compensation expense | (160000) | (114000) | (410000) | (1285000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP research and development expense | 2771000 | 6717000 | 4889000 | 15323000 |
| &nbsp;&nbsp;GAAP intangible assets and other long-lived assets impairment | $— | $— | $— | $448000 |
| &nbsp;&nbsp;Intangible assets, and other long-lived assets impairment |  |  |  | (448000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP intangible assets and other long-lived assets impairment |  |  |  |  |
| &nbsp;&nbsp;GAAP restructuring costs | $— | $1215000 | $— | $5847000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restructuring costs |  | (1215000) |  | (5847000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-GAAP restructuring costs |  |  |  |  |
| Total non-GAAP operating expense | $8834000 | $18786000 | $17282000 | $43146000 |

---

<br>